Christopher‐Paul Milne

588 total citations
34 papers, 378 citations indexed

About

Christopher‐Paul Milne is a scholar working on Economics and Econometrics, Public Health, Environmental and Occupational Health and Physiology. According to data from OpenAlex, Christopher‐Paul Milne has authored 34 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Economics and Econometrics, 7 papers in Public Health, Environmental and Occupational Health and 7 papers in Physiology. Recurrent topics in Christopher‐Paul Milne's work include Pharmaceutical Economics and Policy (17 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Biomedical Ethics and Regulation (7 papers). Christopher‐Paul Milne is often cited by papers focused on Pharmaceutical Economics and Policy (17 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Biomedical Ethics and Regulation (7 papers). Christopher‐Paul Milne collaborates with scholars based in United States, Canada and France. Christopher‐Paul Milne's co-authors include Jon Bruss, Janice M. Reichert, Jonathan M. Davis, Kenneth I. Kaitin, Joshua Cohen, Kristina Cotter, Joseph A. DiMasi, Joyce Tait, Andrew Wilson and Rachael B. Zuckerman and has published in prestigious journals such as Nature Biotechnology, Nature Reviews Drug Discovery and Science Translational Medicine.

In The Last Decade

Christopher‐Paul Milne

33 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher‐Paul Milne United States 11 137 112 63 44 37 34 378
Roberta Joppi Italy 10 326 2.4× 101 0.9× 44 0.7× 24 0.5× 23 0.6× 20 451
Giovanni Tafuri Italy 12 277 2.0× 97 0.9× 51 0.8× 21 0.5× 56 1.5× 22 463
G. Caleb Alexander United States 8 169 1.2× 26 0.2× 54 0.9× 45 1.0× 42 1.1× 11 391
Michael K. Smith United States 11 85 0.6× 61 0.5× 27 0.4× 42 1.0× 15 0.4× 31 551
Entela Xoxi Italy 10 222 1.6× 43 0.4× 23 0.4× 68 1.5× 36 1.0× 20 370
Daniel Tobias Michaeli Germany 14 291 2.1× 51 0.5× 61 1.0× 47 1.1× 26 0.7× 48 550
Thomas Michaeli Germany 13 240 1.8× 40 0.4× 51 0.8× 45 1.0× 27 0.7× 39 467
Marisa Papaluca‐Amati Netherlands 10 75 0.5× 62 0.6× 33 0.5× 53 1.2× 50 1.4× 11 395
Ameeta Parekh United States 10 99 0.7× 48 0.4× 178 2.8× 98 2.2× 38 1.0× 15 587
Gigi Hirsch United States 7 135 1.0× 19 0.2× 37 0.6× 42 1.0× 38 1.0× 15 268

Countries citing papers authored by Christopher‐Paul Milne

Since Specialization
Citations

This map shows the geographic impact of Christopher‐Paul Milne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher‐Paul Milne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher‐Paul Milne more than expected).

Fields of papers citing papers by Christopher‐Paul Milne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher‐Paul Milne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher‐Paul Milne. The network helps show where Christopher‐Paul Milne may publish in the future.

Co-authorship network of co-authors of Christopher‐Paul Milne

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher‐Paul Milne. A scholar is included among the top collaborators of Christopher‐Paul Milne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher‐Paul Milne. Christopher‐Paul Milne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Milne, Christopher‐Paul, et al.. (2024). The state of disaster and resilience literature in British Columbia, Canada. A systematic scoping review. International Journal of Disaster Risk Reduction. 113. 104848–104848.
2.
Yen, Elizabeth, Jonathan M. Davis, & Christopher‐Paul Milne. (2019). Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development. Therapeutic Innovation & Regulatory Science. 53(5). 609–614. 13 indexed citations
3.
Milne, Christopher‐Paul & Kenneth I. Kaitin. (2019). Are Regulation and Innovation Priorities Serving Public Health Needs?. Frontiers in Pharmacology. 10. 144–144. 4 indexed citations
4.
Milne, Christopher‐Paul, et al.. (2017). The Use of Social Media in Orphan Drug Development. Clinical Therapeutics. 39(11). 2173–2180. 12 indexed citations
5.
6.
Milne, Christopher‐Paul, et al.. (2016). Prospects for Harmonizing Regulatory Science Programs in Europe, Japan, and the United States to Advance Regenerative Medicine. Therapeutic Innovation & Regulatory Science. 50(6). 724–733. 7 indexed citations
7.
Cotter, Kristina, et al.. (2016). Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years: From Theory to Therapy. Therapeutic Innovation & Regulatory Science. 50(6). 759–768. 38 indexed citations
8.
Milne, Christopher‐Paul, et al.. (2015). Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry. Clinical Therapeutics. 37(8). 1852–1858. 3 indexed citations
9.
Milne, Christopher‐Paul, et al.. (2015). Complementary Versus Companion Diagnostics: Apples and Oranges?. Biomarkers in Medicine. 9(1). 25–34. 23 indexed citations
10.
Milne, Christopher‐Paul, et al.. (2015). Where is personalized medicine in industry heading?. Nature Reviews Drug Discovery. 14(12). 812–813. 15 indexed citations
11.
Milne, Christopher‐Paul, et al.. (2014). Personalized medicines in late-stage development. Nature Reviews Drug Discovery. 13(5). 324–325. 9 indexed citations
12.
Cohen, Joshua & Christopher‐Paul Milne. (2013). Is the increasing cost of treating rare diseases sustainable?. Expert Opinion on Orphan Drugs. 1(8). 581–583. 6 indexed citations
13.
Milne, Christopher‐Paul & Joyce Tait. (2009). Evolution Along the Government-Governance Continuum: FDA's Orphan Products and Fast Track Programs as Exemplars of "What Works" for Innovation and Regulation. 64(4). 733–753. 13 indexed citations
14.
Milne, Christopher‐Paul & Joyce Tait. (2009). Evolution along the Government-Governance Continuum: Impacts of Regulations on Medicines Innovation in the United States. 107–132. 1 indexed citations
15.
Milne, Christopher‐Paul & Jon Bruss. (2008). The economics of pediatric formulation development for off-patent drugs. Clinical Therapeutics. 30(11). 2133–2145. 81 indexed citations
16.
Milne, Christopher‐Paul. (2006). US and European regulatory initiatives to improve R&D performance. Expert Opinion on Drug Discovery. 1(1). 11–14. 4 indexed citations
17.
Milne, Christopher‐Paul. (2002). Exploring the frontiers of law and science: FDAMA's pediatric studies incentive.. PubMed. 57(3). 491–517. 6 indexed citations
18.
Reichert, Janice M. & Christopher‐Paul Milne. (2002). Public and Private Sector Contributions to the Discovery and Development of ???Impact??? Drugs. American Journal of Therapeutics. 9(6). 543–555. 25 indexed citations
19.
Milne, Christopher‐Paul. (2002). Orphan products—pain relief for clinical development headaches. Nature Biotechnology. 20(8). 780–784. 13 indexed citations
20.
Milne, Christopher‐Paul. (2000). The Health of the World’s Children: What Goes Around, Comes Around. Drug Information Journal. 34(1). 213–221. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberta Joppi Breakdown of academic impact, for papers by Giovanni Tafuri Breakdown of academic impact, for papers by G. Caleb Alexander Breakdown of academic impact, for papers by Michael K. Smith Breakdown of academic impact, for papers by Entela Xoxi Breakdown of academic impact, for papers by Daniel Tobias Michaeli Breakdown of academic impact, for papers by Thomas Michaeli Breakdown of academic impact, for papers by Marisa Papaluca‐Amati Breakdown of academic impact, for papers by Ameeta Parekh Breakdown of academic impact, for papers by Gigi Hirsch
Rankless by CCL
2026